Jasper Therapeutics Inc. (JSPR)
5.87
-0.82 (-12.26%)
At close: Jan 14, 2025, 3:59 PM
5.82
-0.85%
Pre-market Jan 15, 2025, 05:33 AM EST
undefined% (undefined)
| Bid | 5.89 |
| Market Cap | 88.06M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -4.75 |
| PE Ratio (ttm) | -1.24 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 6.07 |
| Volume | 1,237,874 |
| Avg. Volume (20D) | 416,962 |
| Open | 6.67 |
| Previous Close | 6.69 |
| Day's Range | 5.85 - 6.72 |
| 52-Week Range | 5.85 - 31.01 |
| Beta | undefined |
About JSPR
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The co...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 10, 2020
Employees 45
Stock Exchange NASDAQ
Ticker Symbol JSPR
Website https://jaspertherapeutics.com
Analyst Forecast
According to 10 analyst ratings, the average rating for JSPR stock is "Buy." The 12-month stock price forecast is $67.5, which is an increase of 1049.91% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
1 week ago ·
Source
-60.53%
Jasper Therapeutics shares are trading lower. The ...
Unlock content with
Pro Subscription
1 month ago ·
Source
-1.46%
Jasper Therapeutics shares are trading higher after the company announced it dosed its first patient in its Phase 1b/2a EESIAN study evaluating Briquilimab.
